NeuroSense Therapeutics secures Japanese patent for PrimeC ALS treatment
NeuroSense Therapeutics Ltd. has been granted Japanese Patent 7857044 for its ALS drug candidate PrimeC, providing protection through 2042. The patent covers the formulation and synchronized delivery of ciprofloxacin and celecoxib. This follows prior patents in the U.S., Australia, and Brazil, bolstering NeuroSense's global IP portfolio.
*this image is generated using AI for illustrative purposes only.
NeuroSense Therapeutics Ltd. has secured Japanese Patent 7857044 from the Japan Patent Office, covering its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The patent protection extends through 2042, strengthening the company's intellectual property portfolio following recent grants in the U.S., Australia, and Brazil. This development is significant for NeuroSense as it reinforces the proprietary position of its late-clinical stage treatment targeting severe neurodegenerative diseases.
The patent, titled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims. It safeguards the unique formulation and manufacturing process of PrimeC, specifically its synchronized delivery profile of celecoxib and ciprofloxacin. This mechanism is designed to target multiple key pathways underlying ALS progression, offering a novel approach to managing the disease.
Patent Details
The issuance of Japanese Patent 7857044 marks a milestone in NeuroSense's global intellectual property strategy. The patent's claims cover the specific combination and delivery method of the two active ingredients, which are central to PrimeC's therapeutic potential. By securing protection until 2042, NeuroSense aims to maintain a competitive edge in the ALS treatment landscape.
| Aspect | Detail |
|---|---|
| Patent Number | 7857044 |
| Jurisdiction | Japan |
| Protection Period | Through 2042 |
| Claims | 17 |
| Key Components | Ciprofloxacin and celecoxib |
| Primary Focus | Unique formulation and synchronized delivery profile for ALS treatment |
NeuroSense's PrimeC is currently in late-clinical stages, focusing on addressing the complex mechanisms of ALS. The recent patent approvals in multiple jurisdictions underscore the drug's innovative approach and the company's commitment to advancing treatments for neurodegenerative conditions.
How will the Japanese patent protection influence potential partnerships or licensing agreements with local pharmaceutical companies?
What are the next regulatory milestones for PrimeC following the completion of its late-clinical stages?
How does the secured patent portfolio impact NeuroSense's ability to attract further investment for ALS research?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
